Chronic cyclodextrin treatment of murine Niemann-Pick C disease ameliorates neuronal cholesterol and glycosphingolipid storage and disease progression
Cristin D Davidson, Nafeeza F Ali, Matthew C Micsenyi, Gloria Stephney, Sophie Renault, Kostantin Dobrenis, Daniel S Ory, Marie T Vanier, Steven U Walkley, Cristin D Davidson, Nafeeza F Ali, Matthew C Micsenyi, Gloria Stephney, Sophie Renault, Kostantin Dobrenis, Daniel S Ory, Marie T Vanier, Steven U Walkley
Abstract
Background: Niemann-Pick type C (NPC) disease is a fatal neurodegenerative disorder caused most commonly by a defect in the NPC1 protein and characterized by widespread intracellular accumulation of unesterified cholesterol and glycosphingolipids (GSLs). While current treatment therapies are limited, a few drugs tested in Npc1(-/-) mice have shown partial benefit. During a combination treatment trial using two such compounds, N-butyldeoxynojirimycin (NB-DNJ) and allopregnanolone, we noted increased lifespan for Npc1(-/-) mice receiving only 2-hydroxypropyl-beta-cyclodextrin (CD), the vehicle for allopregnanolone. This finding suggested that administration of CD alone, but with greater frequency, might provide additional benefit.
Methodology/principal findings: Administration of CD to Npc1(-/-) mice beginning at either P7 or P21 and continuing every other day delayed clinical onset, reduced intraneuronal cholesterol and GSL storage as well as free sphingosine accumulation, reduced markers of neurodegeneration, and led to longer survival than any previous treatment regime. We reasoned that other lysosomal diseases characterized by cholesterol and GSL accumulation, including NPC disease due to NPC2 deficiency, GM1 gangliosidosis and mucopolysaccharidosis (MPS) type IIIA, might likewise benefit from CD treatment. Treated Npc2(-/-) mice showed benefits similar to NPC1 disease, however, mice with GM1 gangliosidosis or MPS IIIA failed to show reduction in storage.
Conclusions/significance: Treatment with CD delayed clinical disease onset, reduced intraneuronal storage and secondary markers of neurodegeneration, and significantly increased lifespan of both Npc1(-/-) and Npc2(-/-) mice. In contrast, CD failed to ameliorate cholesterol or glycosphingolipid storage in GM1 gangliosidosis and MPS IIIA disease. Understanding the mechanism(s) by which CD leads to reduced neuronal storage may provide important new opportunities for treatment of NPC and related neurodegenerative diseases characterized by cholesterol dyshomeostasis.
Conflict of interest statement
Competing Interests: SUW is an author on a patent for the use of miglustat for the treatment of Niemann-Pick C disease. MTV has been a paid and non-paid consultant for Actelion, which markets miglustat as treatment for Niemann-Pick C disease.
Figures
References
- Pentchev PG, Comly ME, Kruth HS, Vanier MT, Wenger DA, et al. A defect in cholesterol esterification in Niemann-Pick disease (type C) patients. PNAS USA. 1985;82:8247–8251.
- Patterson MC, Vanier MT, Suzuki K, Morris JA, Carstea E, et al. Niemann-Pick disease type C: a lipid trafficking disorder. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. New York: McGraw-Hill Medical Publishing Division; 2001. pp. 3611–3633. The Metabolic & Molecular Bases of Inherited Disease, vol. 3, 8th edition.
- Walkley SU, Suzuki K. Consequences of NPC1 and NPC2 loss of function in mammalian neurons. Biochim Biophys Acta. 2004;1685:48–62.
- Sarna JR, Larouche M, Marzban H, Sillitoe RV, Rancourt DE, et al. Patterned Purkinje cell degeneration in mouse models of Niemann-Pick type C disease. J Comp Neurol. 2003;456:279–291.
- Ohgami N, Ko DC, Thomas M, Scott MP, Chang CC, et al. Binding between the Niemann-Pick C1 protein and a photactivatable cholesterol analog requires a functional sterol-sensing domain. PNAS USA. 2004;101:12473–12478.
- Naureckiene S, Sleat DE, Lackland H, Fensom A, Vanier MT, et al. Identification of HE1 as the second gene of Niemann-Pick C disease. Science. 2000;290:2298–2301.
- Ko DC, Binkley J, Sidow A, Scott MP. The integrity of a cholesterol-binding pocket in Niemann-Pick C2 protein is necessary to control lysosome cholesterol levels. PNAS USA. 2003;100:2518–2525.
- Infante RE, Abi-Mosleh L, Radhakrishnan A, Dale JD, Brown MS, et al. Purified NPC1 protein. I. Binding of cholesterol and oxysterols to a 1278-amino acid membrane protein. J Biol Chem. 2008;283:1052–1063.
- Infante RE, Wang ML, Radhakrishnan A, Kwon HJ, Brown MS, et al. NPC2 facilitates bidirectional transfer of cholesterol between NPC1 and lipid bilayers, a step in cholesterol egress from lysosomes. PNAS USA. 2008;105:15287–15292.
- Sleat DE, Wiseman JA, El-Banna M, Price SM, Verot L, et al. Genetic evidence for nonredundant functional cooperativity between NPC1 and NPC2 in lipid transport. PNAS USA. 2004;101:5886–5891.
- Liu Y, Wu YP, Wada R, Neufeld EB, Mullin KA, et al. Alleviation of neuronal ganglioside storage does not improve the clinical course of the Niemann-Pick C disease mouse. Hum Mol Genet. 2000;9:1087–1092.
- Gondre-Lewis MC, McGlynn R, Walkley SU. Cholesterol accumulation in NPC1-deficient neurons is ganglioside dependent. Curr Biol. 2003;13:1324–1329.
- Lachmann RH, Platt FM. Substrate reduction therapy for glycosphingolipid storage disorders. Expert Opin Investig Drugs. 2001;10:455–466.
- Zervas M, Somers KL, Thrall MA, Walkley SU. Critical role for glycosphingolipids in Niemann-Pick disease type C. Curr Biol. 2001;11:1283–1287.
- Patterson MC, Vecchio D, Prady H, Abel L, Wraith JE. Miglustat for treatment of Niemann-Pick C disease: a randomized controlled study. Lancet Neurol. 2007;6:765–772.
- Griffin LD, Gong W, Verot L, Mellon SH. Niemann-Pick type C disease involves disrupted neurosteriodogenesis and responds to allopregnanolone. Nat Med. 2004;10:704–711.
- Walkley SU. Pathogenic mechanisms in lysosomal disease: a reappraisal of the role of the lysosome. Acta Paediatr. 2007;(Suppl 96):26–32.
- Liu B, Li H, Repa JJ, Turley SD, Dietschy JM. Genetic variations and treatments that affect the lifespan of the NPC1 mouse. J Lipid Res. 2008;49:663–669.
- Liu B, Turley SD, Burns DK, Miller AM, Repa JJ, et al. Reversal of defective lysosomal transport in NPC disease ameliorates liver dysfunction and neurodegeneration in the npc1−/− mouse. PNAS USA. 2009;106:2377–2382.
- Pacheco CD, Kunkel R, Lieberman AP. Autophagy in Niemann-Pick C disease is dependent upon Beclin-1 and responsive to lipid trafficking defects. Hum Mol Genet. 2007;16:1495–1503.
- Liao G, Yao Y, Liu J, Yu Z, Cheung S, et al. Cholesterol accumulation is associated with lysosomal dysfunction and autophagic stress in Npc1−/− mouse brain. Am J Pathol. 2007;171:962–975.
- Jeyakumar M, Thomas R, Elliot-Smith E, Smith DA, van der Spoel AC, et al. Central nervous system inflammation is a hallmark of pathogenesis in mouse models of GM1 and GM2 gangliosidosis. Brain. 2003;126:974–987.
- Irie T, Uekama K. Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation. J Pharm Sci. 1997;86:147–162.
- Goldin E, Roff CF, Miller SPF, Rodriguez-Lafrasse C, Vanier MT, et al. Type C Niemann-Pick disease: a murine model of the lysosomal cholesterol lipidosis accumulates sphingosine and sphinganine in the liver. Biochim Biophys Acta. 1992;1127:303–311.
- Rodriguez-Lafrasse C, Rousson R, Pentchev PG, Louisot P, Vanier MT. Free sphingoid bases in tissues from patients with type C Niemann-Pick disease and other lysosomal storage disorders. Biochim Biophys Acta. 1994;1226:138–144.
- Lloyd-Evans E, Morgan AJ, He X, Smith DA, Elliot-Smith E, et al. Niemann-Pick disease type C1 is a sphingosine storage disease that causes deregulation of lysosomal calcium. Nat Med. 2008;14:1247–1255.
- Walkley SU. Secondary accumulation of gangliosides in lysosomal storage disorders. Semin Cell Dev Biol. 2004;15:433–444.
- Neufeld EF, Muenzer J. The mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. New York: McGraw-Hill Medical Publishing Division; 2001. pp. 3421–3452. The Metabolic and Molecular Basis of Inherited Disease, vol. 3, 8th edition.
- McGlynn R, Dobrenis K, Walkley SU. Differential subcellular localization of cholesterol, gangliosides, and glycosaminoglycans in murine models of mucopolysaccharide storage disorders. J Comp Neurol. 2004;480:415–426.
- Walkley SU, Vanier MT. Secondary lipid accumulation in lysosomal disease. Biochim Biophys Acta. 2009;1793:726–736.
- Hahn CN, del Pilar Martin M, Schroder M, Vanier MT, Hara Y, et al. Generalized CNS disease and massive GM1-ganglioside accumulation in mice defective in lysosomal acid β-galactosidase. Hum Mol Genet. 1997;6:205–211.
- Bhaumik M, Muller VJ, Rozaklis T, Johnson L, Dobrenis K, et al. A mouse model for mucopolysaccharidosis type III A (Sanfilippo syndrome). Glycobiology. 1999;9:1389–1396.
- Lau AA, Crawley AC, Hopwood JJ, Hemsley HM. Open field locomotor activity and anxiety-related behaviors in mucopolysaccharidosis type IIIA mice. Behav Brain Res. 2008;191:130–136.
- Camargo F, Erickson RP, Garver WS, Hossain GS, Carbone PN, et al. Cyclodextrins in the treatment of a mouse model of Niemann-Pick C disease. Life Sci. 2001;70:131–142.
- Monnaert V, Tilloy S, Bricout H, Fenart L, Cecchelli R, et al. Behavior of α-, β-, and γ-cyclodextrins and their derivatives on an in vitro model of blood-brain barrier. J Pharmacol Exp Ther. 2004;310:745–751.
- Jeulin H, Venard V, Carapito D, Finance C, Kedzierewicz F. Effective ribavirin concentration in mice brain using cyclodextrin as a drug carrier: Evaluation in a measles encephalitis model. Antiviral Res. 2009;81:261–266.
- Zidovetzki R, Levitan I. Use of cyclodextrins to manipulate plasma membrane cholesterol content: evidence, misconceptions and control strategies. Biochim Biophys Acta. 2007;1768:1311–1324.
- Chevallier J, Chamoun Z, Jiang G, Prestwich G, Sakai N, et al. Lysobisphosphatidic acid controls endosomal cholesterol levels. J Bio Chem. 2008;283:27871–27880.
- Deng D, Jiang N, Hao SJ, Sun H, Zhang GJ. Loss of membrane cholesterol influences lysosomal permeability to potassium ions and protons. Biochim Biophys Acta. 2009;1788:470–476.
- Lange Y, Ye J, Rigney M, Steck TL. Dynamics of lysosomal cholesterol in Niemann-Pick type C and normal human fibroblasts. J Lipid Res. 2002;43:198–204.
- Atger VM, de la Llera Moya M, Stoudt GW, Rodriguez WV, Phillips MC, et al. Cyclodextrins as catalysts for the removal of cholesterol from macrophage foam cells. J Clin Invest. 1997;99:773–780.
- Pfrieger FW. Outsourcing in the brain: do neurons depend on cholesterol delivery by astrocytes? Bioessays. 2003;25:72–78.
- Benarroch EE. Brain cholesterol metabolism and neurologic disease. Neurology. 2008;71:1368–1373.
- Zhang M, Strnatka D, Donohue C, Hallows JL, Vincent I, et al. Astrocyte-only Npc1 reduces neuronal cholesterol and triples lifespan of Npc1−/− mice. J Neurosci Res. 2008;86:2848–2856.
- Rajewski RA, Stella VJ. Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery. J Pharm Sci. 1996;85:1142–1169.
- Gould S, Scott RC. 2-Hydroxypropyl-beta-cyclodextrin (HP-beta-CD): a toxicology review. Food Chem Toxicol. 2005;43:1451–1459.
- Loftus SK, Morris JA, Carstea ED, Gu JZ, Cummings C, et al. Murine model of Niemann-Pick C disease: mutation in a cholesterol homeostasis gene. Science. 1997;277:232–235.
- Fujita N, Suzuki K, Vanier MT, Popko B, Maeda N, et al. Targeted disruption of the mouse sphingolipid activator protein gene: a complex phenotype, including severe leukodystrophy and wide-spread storage of multiple sphingolipids. Hum Mol Genet. 1996;5:711–725.
- Miscenyi MC, Dobrenis K, Stephney G, Pickel J, Vanier MT, et al. Neuropathology of the Mcoln1(−/−) knockout mouse model of mucolipidosis type IV. J Neuropathol Exp Neurol. 2009;68:125–135.
Source: PubMed